artificial intelligence

Overview

Artificial intelligence (AI) refers to the simulation of human cognitive processes—including learning, reasoning, and problem-solving—by computational systems, and has emerged as one of the most transformative technological forces in modern biomedicine. In the medical and life sciences context, AI encompasses a broad family of techniques including machine learning (ML), deep learning, natural language processing, and large language models, each enabling computers to identify complex patterns in high-dimensional data that exceed the practical limits of human analysis. Its core value in healthcare lies in its capacity to integrate heterogeneous datasets—from clinical records and medical imaging to multi-omics molecular profiles—into unified predictive and diagnostic frameworks.

The biological significance of AI in medicine is not rooted in a single mechanism but rather in its function as an integrative analytical layer. By processing genomics, transcriptomics, proteomics, and metabolomics data simultaneously, AI-driven models can map disease biology at an unprecedented resolution, linking molecular alterations to clinical phenotypes, treatment responses, and patient outcomes. This positions AI not merely as a computational convenience but as a fundamental infrastructure for precision medicine, enabling the identification of actionable biomarkers, the optimization of drug formulations, the stratification of patient risk, and the acceleration of therapeutic discovery across virtually every disease domain.

Focus of Latest Publications

Recent publications on artificial intelligence span both clinical deployment and broader translational applications. In healthcare, studies examined AI-enabled tools for melanoma assessment, stroke triage, and post-deployment surveillance of AI medical devices. A retrospective analysis of dermoscopic images in primary care found that a convolutional neural network tool was more likely to correctly classify elevated lesions as benign than macular lesions, while a ruler placed over the lesion increased false suspicion of melanoma, suggesting image features can affect specificity and may inform optimization. In acute ischemic stroke care, an AI-driven triage system was evaluated for its impact on workflow efficiency and transfer optimization across a large network of thrombectomy hubs and spokes. Another study proposed a structured, decision-oriented framework for post-deployment monitoring of AI medical devices, emphasizing governance-linked corrective action to support safer integration into routine clinical practice.

Several publications focused on the ethical, safety, and equity implications of AI in medicine. One analysis of ChatGPT Health argued that integrating personal medical records and consumer health data into a large language model-based chatbot could widen health care disparities rather than reduce them, with risks including dangerous self-rationing and self-medication, inaccurate emergency triage, erosion of health communication, and reinforcement of confirmation and anchoring bias. The authors proposed solidarity-based policy interventions and safeguards to ensure AI tools complement rather than replace human care. In parallel, an AI-assisted framework for ethical machine learning use in healthcare used ChatGPT in first-stage drafting to develop the ETHICS protocol, a clinician-facing mnemonic covering equity and fairness, transparency and patient-centered care, human oversight and clinical integrity, information privacy and data governance, continuous improvement and sustainability, and support and education for professionals. The protocol was refined through human verification, expert review, and scenario testing, with improved readability and strong expert endorsement.

Other recent reviews placed artificial intelligence within broader biomedical and translational innovation pipelines. In drug development and delivery, AI and machine learning were described as increasingly important for predictive modeling, simulation, classification, optimization, and de-risking across the development process, including oral absorption assessment and drug product development. In nanomedicine, AI and active learning were presented as enabling automated data analysis and experimental optimization in organ-on-chip platforms, supporting self-driving discovery workflows. In ophthalmology, AI-driven precision medicine was highlighted as part of an expanding therapeutic landscape for diabetic retinopathy alongside advanced drug delivery systems and gene-based approaches. Outside medicine, AI was also discussed as a tool for metabolomics-guided engineering of drought-resilient crops and as a component of personalized, biomarker-driven dermatology strategies, reflecting its growing role in predictive and adaptive systems across life sciences.